Strategies for Bioavailability Enhancement of Poorly Soluble or Poorly Permeable Drugs - 6th Edition
Publication Date: January 2007
Technology Catalysts International (TCI) has developed Strategies for Bioavailability Enhancement of Poorly Soluble and Poorly Permeable Drugs, a substantially updated Sixth Edition to the former Poorly Soluble or Poorly Permeable Drugs report series. After extensive analysis of the current pharmaceutical market, TCI provides this new edition with numerous opportunities for enhancing the bioavailability of BCS Class IV drug candidates with novel drug delivery technologies. This comprehensive report presents an inside view for companies interested in understanding or participating in this considerable market.
The Sixth Edition is unique in three significant ways: it clarifies the often vague terms and
concepts associated with poorly soluble and poorly permeable drugs; it offers a vast listing of BCS
Class IV drugs and drug properties; and finally, it discloses tried-and-true strategies that have
yielded highly profitable products, including both brand and generic reformulations. This report
dispenses unparalleled information on the BCS Class IV market, products, and technologies.
The report includes an in-depth introduction to bioavailability enhancement terminology,
insightful market analysis of over 242 reviewed BCS Class IV drugs, numerous strategies and
licensing opportunities for business development, straightforward scientific explanations, and
over 165 novel drug delivery technologies applicable to poorly bioavailable drugs that are being
developed by over 144 companies. Each drug has confirmed solubility and bioavailability properties,
market status, pertinent technology, and pipeline records. Each technology profile contains: technology description, technology applications, technology offer (business opportunity), stage of development, patents/publications, competitive advantage, company summary, and complete contact information.
New to this Sixth Edition:
- Emphasis on BCS Class IV drugs
- Over 200 additional drug candidates verified as business opportunities
- Over 75 BCS Class IV pipeline drugs tracked
- Market strategies involving both brand and generic drugs
- Definitions of complex concepts
- Over 65 new drug delivery technologies added
- Additional technology sections that include: microparticles, solid emulsions, and covalent conjugation
- Updated market analysis
